Resistell is a antibiotic resistance test.
resistell has raised €12M across 2 funding rounds from 6 investors, most recently a Series B round in Dec 2022. Based in Basel, Switzerland; founded 2018; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-12-20 | Series B | €8.6M | Launchpad Capital,EIC Fund,OCCIDENT,Private Investors,Trumpf Venture,Zürcher Kantonalbank | View deal → |
| 2019-10-01 | Series A | €3.2M | OCCIDENT | View deal → |
